Purpose: To investigate how biologically relevant markers change in response to anti-angiogenic therapy in metastatic renal cell carcinoma (mRCC) and correlate these changes with outcome. 
Translational relevance: The mechanisms of acquired resistance to VEGFtargeted therapy have not been fully elucidated. By investigating renal tumor tissue taken before and after treatment, this study demonstrates that consistent changes to tumor biomarkers occur with therapy. These dynamic changes occur in clinically relevant biomarkers such as PD-1, MET and FGF-2. Candidate drugs targeting these 3 proteins are currently under investigation in renal cancer. Our data shows that CD31 (a vascular marker) falls with treatment. Failure to achieve a sustained reduction in CD31 expression is associated with poor prognosis, suggesting that continued vascular suppression is important to maximize treatment response. Treatment is associated with an increase in tumor grade and Ki-67 expression, which suggests the development of a more aggressive tumor phenotype.
Introduction
Anti-angiogenic tyrosine kinase inhibitors (TKIs) are established as first line therapy for metastatic clear cell renal cancer (mRCC) (1, 2) . However, a marked variability of response to therapy occurs. A minority of tumors are inherently resistant to therapy (early progression) while a larger proportion are initially sensitive and subsequently develop resistance to therapy (delayed progression) (3) . There are currently no clinically validated tumor biomarkers for renal cancer which predict the onset of treatment resistance (4) . Most studies to date have focused on tumor samples taken prior to therapy, however, preclinical data show that treatment with anti-angiogenic agents induces dynamic changes in tumor biology (5, 6) . We hypothesise that identification of these dynamic changes is required to elucidate the mechanisms of resistance to anti-angiogenic agents.
Here we prospectively collected sequential tissue from three trials that were all designed to investigate the role of anti-angiogenic tyrosine kinase inhibitors (TKIs) prior to planned nephrectomy in treatment naïve mRCC patients. The expression of relevant biomarkers before and after 12-16 weeks of TKI therapy was measured from the primary renal tumor. The absolute levels and dynamic changes to biomarkers were assessed and correlated with outcome in 85 patients. Patients with early or delayed disease progression were studied separately and compared with non-progressors. The markers examined were selected because they fulfilled one or more of the following criteria: (a) markers linked mechanistically with response and / or resistance to anti-angiogenic therapy, (b) markers of pathways that are currently under investigation as a therapeutic option in RCC, and (c) markers of immunological significance. Markers examined included: vessel density (CD31), pericyte coverage, Ki67, FGF2, MET receptor, PDL-1, phosphorylated S6K, CD45, CD3 or FOXP3 (7) (8) (9) (10) (11) (12) (13) (14) (15) . Multiple sampling of the same tumor was performed to further explore the importance of heterogeneity in RCC. This included histological, chromosomal and DNA methylation analysis.
Research. The hypothesis was that VEGF therapy resulted in dynamic changes to specific biomarkers which correlated with outcome, despite the presence of tumor heterogeneity. Our biomarker work was performed on tissue from the renal cancer and not metastatic sites, which are responsible for mortality.
Therefore the final part of our work examined the relationship between the primary renal tumor and metastatic sites. This was performed by comparing metabolic response to VEGF therapy in these sites using FDG-PET.
Patients, Materials and Methods

Clinical trials
Patients included in this analysis originated from 3 independent prospective single arm phase II studies, two using sunitinib and one pazopanib (16) (17) (18) . All Array CGH and DNA methylation analysis (MethylCap-seq) was performed on the same sequential frozen pairs (n=14). Analysis was performed once from the biopsy and in triplicate from the nephrectomy sample for each patient. Once labelled 20ug of test and reference sample were combined and added to a Nimblegen 12x135 array and hybridised, following which slides were scanned (NimbleGen MS 200 Microarray Scanner). Array CGH data were pre-processed and analysed using an in-house R script (BACE.R) in R version 2·13·0, as previously described (19, 20) . Categorical aCGH states (i.e.
gains, losses, and amplifications) were used for clustering, employing Wards clustering algorithm based upon Euclidean distance.
MethylCap-seq involves the in vitro capture of methylated DNA and subsequent analysis of enriched fragments by massively parallel sequencing (21) . Unsupervised hierarchical clustering analysis was performed. Data analysis was performed with R 2.15.3.
Protein analysis
A tissue microrarray (TMA) was constructed from biopsy and nephrectomy tissue samples. For protein analysis, sections were pre-treated using heatmediated antigen retrieval with sodium citrate buffer. The following antibodies were used to assess protein expression; CD31 (1:600, AstraZeneca), FGF-2 
Radiological and FDG PET-CT assessment
All patients were assessed according to RECIST v1·1. CT was performed at base line, prior to nephrectomy (week [12] [13] [14] and after nephrectomy (week [16] [17] [18] . Patients then followed up with regular imaging until progression.
Radiological analysis took place centrally.
FDG PET CT scans were performed at baseline and prior to nephrectomy (48 hours after cessation of VEGF TKI therapy) in 34 patients. Changes in SUV to positive lesions (SUV >2·5) with therapy was measured. A correlation between the primary renal lesion and the metastatic sites was examined. The correlation between changes in SUV and outcome in this population had been previously published (22) .
Statistical analysis
Analysis of the data took place centrally in November 2012. Descriptive statistics were used to compare groups. Univariable and multivariable analysis was performed. Further analysis was performed to investigate if dynamic changes to biomarkers correlated with outcome. Student's t-tests were used to compare biomarker levels in progressors and non-progressors.
A p-value of <0.05 was considered to be significant. Outcome was estimated using the Kaplan-Meier method. A Fisher's Exact test was used to compare groups expressing different histopathological features.
Research. 
Results
Patient characteristics
The CONSORT diagram in Figure 1 shows the disposition of patients at baseline and their subsequent course on study. All 85 patients were diagnosed with untreated metastatic clear cell RCC. All patients started VEGF targeted therapy with the intention of having subsequent tissue taken. Table 1 compares patient's characteristics according to their best response to therapy.
Seventeen patients had early disease progression while 24 patients had delayed progression and 44 were in the non-progressor group. Survival was significantly different in these three groups with early progressors having the worst outcome and those without progression having the best outcome (see Table 1 ). The survival for patients treated with pazopanib and sunitinib was similar (HR for pazopanib =1·16 [95% CI: 0·64-2·1]). A number of patients did not have a nephrectomy (n=19). Prior progression of disease/cessation of therapy (n=17) being the most common reason for this.
Biomarker expression and outcome from baseline tissue
To investigate biomarkers associated with early or delayed progression, baseline untreated tissue was analysed (Figure 2) . None of the 10 biomarkers correlated with progression.
The effect of treatment on tumor pathology and biomarkers
Paired tumor tissue showed a significant increase in Fuhrman grade (increased = 61% of patients, vs. reduction = 29%, p<0·05), Ki67 (increased = 63%, vs. reduction=23%. p<0·05) and necrosis (increased=58%, vs. 
Biomarker expression and outcome from treated tissue
Subsequently we examined if any of the biomarkers which significantly changed with therapy ( Figure 3a ) correlated with delayed progression of disease. Ki-67 and CD31 expression was significantly higher in tissue taken from patients with delayed progression compared to non-progressors (p<0·05 for both) (Figure 3b ).
An increase in CD31 with therapy also correlated with reduced overall survival (p<0.05). The only other biomarker in which a change was associated with a poor outcome was Fuhrman grade, where an increase was associated with a poor outcome (p<0.05).
The relationship between biomarker expression and overall survival
In multivariable analysis, significant baseline prognostic factors included Heng 
Discussion
There is currently a lack of tissue biomarkers to predict response to VEGF receptor-targeted TKIs. In this work, sequential tissue taken before and during TKI treatment was used to explore the hypothesis that dynamic changes to biomarker expression occur in resistance. We focused on the correlation of biomarker expression with progression (initial and delayed) rather than response. This is because initial response does not appear to correlate with outcome (unlike progression) and usually occurs early in the treatment process before acquired resistance appears (23) . Correlation between radiological response (RECIST v1.1) and biomarker was performed but did not identify prognostic changes (data not shown).
Efficacy of VEGF receptor-targeted TKIs is thought to stem primarily from suppression of tumor angiogenesis. Here, TKI treatment significantly reduced tumor vessel density, supporting recent findings obtained in sequential tissue from mRCC patients (12) . Importantly, we show also that failure to achieve a reduction in vessel density is associated with progression of disease.
Continued suppression of the vasculature is therefore important for continued clinical response, supporting the results of a recent randomised phase III trial (24) . The inhibitory effect of TKIs on the PI3K pathway (pS6K) demonstrated the broad effect of these agents and suggests possible overlapping mechanism of action with the mTOR inhibitors which also target the PI3K pathway. This may be a potential explanation for cross resistance that is speculated to occur between these 2 classes of agents in mRCC.
Preclinical studies suggest that VEGF-targeted therapy may increase tumor aggressiveness, including accelerated tumor growth (25) , increased tumor invasion (26) and increased metastasis (25, 26) . If manifested in patients, these effects would limit therapeutic efficacy, however, there is little or no compelling clinical evidence that VEGF-targeted therapy leads to increased tumor aggressiveness (27) . Here we show that tumor grade and tumor cell proliferation were both increased in mRCC patients after treatment with VEGF high baseline levels of pericyte coverage correlate with a poor outcome, supporting previous work in RCC (33) . Conflicting data also exist regarding the effects of anti-angiogenic therapy on pericyte coverage (32, 34, 35 ). Here we demonstrate that therapy can exert opposing effects on pericyte coverage (increase in 13%, decrease in 26% and no change in 61%). We also observed that a reduction in pericyte coverage adversely effected survival in multivariable analysis. This may be related to the fact that pericyte loss can compromise tumor vessel integrity, promoting metastasis (32, 35) . Since loss of pericytes was not associated with progression in our study, but did strongly associate with overall survival, there may be a tumor growth-independent effect of pericyte loss on outcome.
Immune therapy has been used in renal cancer and is currently under Recent exome analysis revealed the existence of significant regional heterogeneity from one patient with mRCC (38) . Our histology, protein and chromosomal analysis shows marked intra-tumoral heterogeneity across a cohort of patients. However DNA methylation results showed all samples from individual patients clustered. This suggests the variability seen in protein expression and histology results more from genetic rather than epigenetic instability. Consistent chromosomal changes were not seen with sunitinib treatment. This may in part be due to the marked heterogeneity.
The presence of heterogeneity is challenging as it may mask the detection of biologically significant changes due to sampling bias. However, despite this heterogeneity, we still observed significant changes in several key biomarkers, including CD31, Ki67, S6K, PDL-1, MET receptor and FGF2. In our opinion, the ability to detect a significant change in these biomarkers 
across a sample that is intrinsically heterogeneous, only acts to further reinforce the biological significance of these changes.
Finally, a positive correlation between a metabolic response in the primary tumor and the metastatic sites occurred, suggesting that primary and metastatic sites may respond in a similar fashion to therapy. However, it does not necessarily mean that dynamic changes to biomarkers in the metastatic sites match those seen in the primary tumor. Collection of sequential tissue from specific metastatic sites is extremely challenging. Therefore, further exploration of this relationship may not be possible.
There are several shortcomings in this work. Specifically, not all patients were able to have sequential tissue taken due to lack of excess tissue for sampling and patients coming off study. Also, the tissue originated from three rather than one study (although they were almost identical in design). 
